Abstract
Phosphodiesterases (PDEs) play a decisive role in cyclic nucleotide-mediated intracellular signaling. As PDEs are expressed in a variety of tissues, selectivity is a prerequisite for a therapeutically applicable PDE inhibitor. Sildenafil, vardenafil, and tadalafil are selective for PDE5, with vardenafil exhibiting the highest potency and minimal inhibition of other PDEs, with the exception of PDE6. Tadalafil is extremely selective for PDE5, but also potently inhibits PDE11, an enzyme with unknown physiological function. As PDE1 is expressed in the brain, myocardium, and vascular smooth muscle cells, nonselectivity with respect to this enzyme (selectivity: tadalafil>vardenafil>sildenafil) may result in vasodilation and tachycardia. Inhibition of PDE6 (selectivity: tadalafil>vardenafil≅sildenafil), which is expressed only in retina and functions in visual transduction, can transiently disturb vision. PDE5 inhibitors may also indirectly inhibit PDE3 by increasing cyclic guanosine monophospate levels, thereby elevating heart rate and vasodilation while inhibiting platelet aggregation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 8 print issues and online access
$259.00 per year
only $32.38 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Saenz de Tejada I et al. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int J Impot Res 2001; 13: 282–290.
Porst H . IC351 (tadalafil, Cialis): update on clinical experience. Int J Impot Res 2002; 14(Suppl 1): S57–S64.
Turko IV, Ballard SA, Francis SH, Corbin JD . Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (type 5) by sildenafil and related compounds. Mol Pharmacol 1999; 56: 124–130.
Saenz de Tejada I, Frutos JA, Gaudo M, Florio V . Comparative selectivity: profiles of tadalafil, sildenafil and vardenafil using an in vitro phosphodiesterase activity assay. Int J Impot Res 2002; 14(Suppl 4): S20–S32.
Corbin JD, Francis SH . Pharmacology of phosphodiesterase-5 inhibitors. Int J Clin Pract 2002; 277: 47581–47587.
Gbekor E et al. Selectivity of sildenafil and other phosphodiesterase type 5 (PDE5) inhibitors against all human phosphodiesterase families. Eur Urol 2002; 42(Suppl 1): 63.
Kim NN et al. Inhibition of cyclic GMP hydrolysis in human corpus cavernosum smooth muscle cells by vardenafil, a novel selective phosphodiesterase type 5 inhibitor. Life Sci 2001; 69: 2249–2256.
Bardou M et al. Hypoxic vasoconstriction of rat main pulmonary artery: role of endogenous nitric oxide, potassium channels, and phosphodiesterase inhibition. J Cardiovasc Pharmacol 2001; 38: 325–334.
Stief CG . Phosphodiesterase inhibitors in the treatment of erectile dysfunction. Drugs Today 2000; 36: 93–99.
Moreland RB, Goldstein II, Kim NN, Traish A . Sildenafil citrate, a selective phosphodiesterase type 5 inhibitor. Trends Endocrinol Metab 1999; 10: 97–104.
McGrouther C et al. Biochemical in situ hybridisation (ISH) and immunohistochemical (ICH) characterisation of phosphodiesterase type 5 (PDE5) expression in human corpus cavernosum (CC) and cardiac tissue. Int J Impot Res 2000; 12(Suppl 1): S27.
Burslem M, Harrow J, Lanfear I, Phillips SC . Modulation of PDE11A activity. Patent # EP 12 11 313 A2, 2002.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bischoff, E. Potency, selectivity, and consequences of nonselectivity of PDE inhibition. Int J Impot Res 16 (Suppl 1), S11–S14 (2004). https://doi.org/10.1038/sj.ijir.3901208
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.ijir.3901208
Keywords
This article is cited by
-
Pharmacokinetics, mass balance, and metabolism of [14C]TPN171, a novel PDE5 inhibitor, in humans for the treatment of pulmonary arterial hypertension
Acta Pharmacologica Sinica (2023)
-
Avanafil as a Novel Therapeutic Agent Against LPS-Induced Acute Lung Injury via Increasing CGMP to Downregulate the TLR4-NF-κB-NLRP3 Inflammasome Signaling Pathway
Lung (2022)
-
Sulfur-containing therapeutics in the treatment of Alzheimer’s disease
Medicinal Chemistry Research (2021)
-
Homogeneous single-label cGMP detection platform for the functional study of nitric oxide-sensitive (soluble) guanylyl cyclases and cGMP-specific phosphodiesterases
Scientific Reports (2020)
-
Phosphodiesterase 5 inhibition improves contractile function and restores transverse tubule loss and catecholamine responsiveness in heart failure
Scientific Reports (2019)